SB 9200

Drug Profile

SB 9200

Alternative Names: SB-9200

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator Spring Bank Pharmaceuticals
  • Developer National Institutes of Health (USA); Spring Bank Pharmaceuticals
  • Class Antivirals; Nucleotides; Small molecules
  • Mechanism of Action DDX58 protein stimulants; Immunostimulants; NOD2 protein antagonists; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatitis C

Highest Development Phases

  • Phase II Hepatitis B
  • Phase I Hepatitis C
  • Preclinical Norovirus infections; Respiratory syncytial virus infections
  • Research Dengue; Japanese encephalitis; West Nile virus infections
  • Suspended Hepatitis D; HIV infections

Most Recent Events

  • 06 Jan 2017 Phase-II clinical trials in Hepatitis B (Treatment-naive) in South Korea, Hong Kong (PO) (NCT02741557)
  • 19 Dec 2016 Spring Bank Pharmaceuticals and Arbutus Biopharma enter into a preclinical collaboration for combination of SB 9200 and AB 423 for Hepatitis B
  • 06 Oct 2016 Arrowhead Pharmaceuticals and Spring Bank Pharmaceuticals intend to amend the protocol of the phase IIb MONARCH study to include a combination arm of ARC 520, SB 9200 and a direct-acting antiviral
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top